Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DIJON · Jan 23, 2023
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the role of immune cells in the development of coronary atherosclerosis, which is a condition where fatty deposits build up in the arteries and can lead to serious heart problems. Researchers want to understand how these immune cells change their function and contribute to plaque formation. They will compare blood samples from patients with atherosclerosis to those without it, using a new method that doesn’t require invasive procedures.
The study is open to adults aged 65 to 74 who are scheduled for cardiac surgery. Participants will be divided into two groups: one group will have atherosclerosis and the other will not. During the month-long study, blood samples will be collected as part of the usual care provided during their hospital stay. It’s important to note that certain individuals, such as those on specific medications that affect cell function or women who are pregnant or breastfeeding, will not be eligible to participate. If you meet the criteria and agree to join, you will help researchers gather valuable information that could improve understanding and treatment of heart disease.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Person who provides oral consent
- Group 1:
- • - Patient scheduled for cardiac bypass surgery (isolated procedure) with extracorporeal circulation
- Group 2:
- • Patient scheduled for valve ou ascending aorta surgery with extracorporeal circulation
- • No coronary lesion
- • No peripheral arterial disease (limbs, carotids, aortic aneurysm)
- Exclusion Criteria:
- • Person not affiliated with national health care system
- • Medication that alters mitochondrial function (Chloroquine, hydroxychloroquine, rapamycin, carbamazepine, resveratrol, sildenafil)
- • Person under a legal protection measure (curatorship, guardianship, tutorship)
- • Pregnant, parturient or breastfeeding women
- • Major unable to express consent
- • Minor
About Centre Hospitalier Universitaire Dijon
The Centre Hospitalier Universitaire Dijon (CHU Dijon) is a leading academic medical institution in France, dedicated to advancing healthcare through innovative research and clinical trials. With a focus on patient-centered care, CHU Dijon integrates comprehensive medical services with cutting-edge research initiatives across various specialties. The institution is committed to enhancing clinical outcomes and improving health standards by facilitating rigorous scientific investigations and collaborations with national and international partners. By prioritizing ethical practices and adherence to regulatory standards, CHU Dijon aims to contribute significantly to the development of new therapies and medical technologies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dijon, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials